NASDAQ · SNTI
Senti Biosciences Holdings, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SNTI: Nov 12, 2026
Senti Biosciences Holdings, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-0.69.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Dec 2026 | $-0.44 | $-0.44 | $-0.44 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Quiver Quantitative- Fintel · Oct 27, 9:38 PM EDTSenti Biosciences, Inc. Announces Board Resignation of Edward Mathers and October 30, 2026 Record Date for CVR DistributionOn October 27, 2026, Edward Mathers notified the Board of Directors of Senti Biosciences Holdings, Inc. of his decision to resign from the Board, effective immediately. In connection with his resignation, Mr. Mathers also resigned from all committees of the Board on which he serv
- RTTNews · May 14, 11:33 AM EDTSenti Reports Q1 Loss Of $4 Mln; Advances SENTI-202 In Phase 1 Trial In Leukemia(RTTNews) – Senti Biosciences Holdings Inc. (SNTI), a clinical-stage biotechnology company, on Thursday announced its first quarter financial results, and highlighted various business developments.
- RTTNews · Dec 9, 11:35 PM ESTAfter-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers(RTTNews) – Biotech stocks showed sharp moves in extended trading, with several names rebounding after steep regular-session losses. Fresh clinical data, FDA designations, and financing announcements drove momentum across the sector, highlighting catalysts that investors are watc
- Fintel · Dec 9, 7:03 PM ESTChardan Capital Maintains Senti Biosciences (SNTI) Buy RecommendationFintel reports that on December 9, 2025, Chardan Capital maintained coverage of Senti Biosciences (NasdaqCM:SNTI) with a Buy recommendation. Analyst Price Forecast Suggests 380.13% Upside
- RTTNews · Dec 9, 10:37 AM ESTSenti Biosciences Secures FDA RMAT Designation For SENTI-202(RTTNews) – Senti Biosciences, Inc. (SNTI) on Tuesday announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to SENTI-202, its off-the-shelf CAR-NK therapy being developed for relapsed or refractory AML and other hematologic cancers.
- RTTNews · Dec 9, 9:45 AM ESTSenti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up(RTTNews) – Senti Biosciences, Inc. (SNTI), Tuesday announced new data from its ongoing trial of SENTI-202, evaluating the safety, efficacy, and pharmacodynamics of the treatment, when administered after Fludarabine/lymphodepletion in patients with relapsed or refractory Acute My
- RTTNews · Dec 9, 9:41 AM ESTSenti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML(RTTNews) – Senti Biosciences, Inc. (SNTI), Tuesday presented new data from its ongoing multinational Phase 1 trial evaluating SENTI-202 for treating patients with relapsed or refractory Acute Myeloid Leukemia or AML at ASH 2025.
- Fintel · Nov 21, 1:17 PM ESTLeerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform RecommendationFintel reports that on November 21, 2025, Leerink Partners initiated coverage of Senti Biosciences (NasdaqCM:SNTI) with a Outperform recommendation. Analyst Price Forecast Suggests 632.60% Upside
- RTTNews · Nov 16, 11:41 PM ESTRepare +30%, Nuvalent +9% Lead After-Hours Biotech Gains(RTTNews) – The after-hours session on Friday, November 14, 2025, brought notable moves across several biotech and therapeutics names, as corporate updates, financial results, and strategic announcements drove sharp price reactions. From acquisition agreements to pivotal trial mi
- Fintel · Oct 14, 8:02 AM EDTHC Wainwright & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy RecommendationFintel reports that on October 14, 2025, HC Wainwright & Co. initiated coverage of Senti Biosciences (NasdaqCM:SNTI) with a Buy recommendation. Analyst Price Forecast Suggests 719.64% Upside
- Quiver Quantitative · Jul 18, 9:00 AM EDTSenti Biosciences, Inc. Appoints Bryan Baum to Board of DirectorsSenti Biosciences appoints Bryan Baum to its Board of Directors, enhancing its expertise in biotechnology and investment.
- Quiver Quantitative · Jun 30, 9:21 AM EDTSenti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight SeriesSenti Biosciences discusses its Gene Circuit platform and SENTI-202 therapy advancements in Nasdaq's Amplify Spotlight Series.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Senti Biosciences Holdings, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.